<SEC-DOCUMENT>0001144204-16-129824.txt : 20161027
<SEC-HEADER>0001144204-16-129824.hdr.sgml : 20161027
<ACCEPTANCE-DATETIME>20161027133802
ACCESSION NUMBER:		0001144204-16-129824
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161027
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161027
DATE AS OF CHANGE:		20161027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		161954925

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v451469_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT PURSUANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
<B>October 27, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>ABEONA THERAPEUTICS INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Delaware</U></B></FONT></TD>
    <TD STYLE="width: 30%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>0-9314</U></B></FONT></TD>
    <TD STYLE="width: 35%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>83-0221517</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>3333 Lee Parkway, Suite 600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Dallas, TX 75219</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>(214)-665-9495</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>N/A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see<I>&nbsp;</I>General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01.&nbsp;&nbsp;&nbsp;&nbsp;Other Events </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 27, 2016, Abeona Therapeutics
Inc. issued a press release entitled &ldquo;Abeona Therapeutics Announces Pricing of Public Offering of Common Stock&rdquo;. The
full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Statements
and Exhibits. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B><U>Exhibit No.</U></B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Description</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt">99.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Press release dated October
27, 2016, entitled &ldquo;Abeona Therapeutics Announces Pricing of Public Offering of Common Stock&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Abeona Therapeutics Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 51%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 30%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Stephen B. Thompson</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Stephen B. Thompson</FONT><BR>
<FONT STYLE="font-size: 10pt">Vice&nbsp;President&nbsp;Finance </FONT><BR>
<FONT STYLE="font-size: 10pt">Chief&nbsp;Accounting Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: October 27, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Exhibit
Number</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">99.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Press release dated October
27, 2016, entitled &ldquo;Abeona Therapeutics Announces Pricing of Public Offering of Common Stock&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v451469_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Abeona Therapeutics Announces<BR>
Pricing of Public Offering of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>New York, NY, and Cleveland, OH</B>
&ndash; <B>October 27, 2016 &ndash; </B>Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical stage biopharmaceutical company focused on
developing therapies for life-threatening rare genetic diseases, <FONT STYLE="background-color: white">announced the pricing of
an underwritten public offering of 6,000,000 shares of common stock at a public offering price of $7.00 per share. The gross offering
size for this offering is expected to be approximately $42,000,000 million, before deducting the underwriting discounts and commissions
and estimated offering expenses payable by the Company. The Company has granted to the underwriters participating in the offering
a 30-day option to purchase up to an additional 900,000 shares of common stock. The offering is expected to close on or about November
1, 2016, subject to customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The
Company currently intends to use the net proceeds of this offering for working capital and general corporate purposes, including,
without limitation, development of the Company&rsquo;s product candidates and general and administrative expenses. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Jefferies
LLC is acting as the sole book-running manager for the offering. Cantor Fitzgerald &amp; Co. is acting as lead manager and FBR
Capital Markets &amp; Co., H.C. Wainwright &amp; Co., JonesTrading Institutional Services LLC and Maxim Group LLC are acting as
co-managers for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The
securities described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-205128) that
was filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on June 22, 2015 and that was declared effective
by the SEC on July 23, 2015. The offering will be made only by means of the written prospectus and prospectus supplement that form
a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering will be
filed with the SEC and will be available on the SEC&rsquo;s website at www.sec.gov. Copies of the final prospectus supplement and
the accompanying prospectus, when available, may also be obtained by request at Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 821-7388, e-mail: Prospectus_Department@Jefferies.com.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>The
securities described above have not been qualified under any state blue sky laws. This press release does not constitute an offer
to sell or the solicitation of offers to buy any securities of Abeona being offered, and shall not constitute an offer, solicitation
or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Abeona:</B> <FONT STYLE="background-color: white">Abeona
Therapeutics Inc. is a clinical stage biopharmaceutical company developing gene and plasma-based therapies for life-threatening
rare genetic diseases. Abeona's lead programs are ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based
gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB, respectively). Abeona is also developing EB-101 (gene-corrected skin
grafts) for recessive dystrophic epidermolysis bullosa (RDEB), </FONT>EB-201 for epidermolysis bullosa (EB), <FONT STYLE="background-color: white">ABO-201
(AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene therapy for treatment of infantile Batten disease
(INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder </FONT>and ABO-302 using a novel CRISPR/Cas9-based gene editing
approach to gene therapy for rare blood diseases<FONT STYLE="background-color: white">. In addition, Abeona has a plasma-based
protein therapy pipeline, including SDF Alpha&trade; (alpha-1 protease inhibitor) for inherited COPD, using its proprietary SDF&trade;
(Salt Diafiltration) ethanol-free process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release contains certain
statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve
risks and uncertainties. These statements include, without limitation, our anticipated offering, anticipated use of proceeds and
plans and prospects for Abeona and other statements including the words &ldquo;may,&rdquo; will,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; expect,&rdquo; &ldquo;intend,&rdquo; and similar expressions (as well as other words
or expressions referencing future events, conditions or circumstances) constitute and intended to identify forward-looking statements.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors,
including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms, or
at all, and such other risk factors as are set forth in the Company's Annual Reports on Form 10-K and other reports filed by the
Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking
statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release,
whether as a result of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Christine Silverstein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vice President, Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Abeona Therapeutics Inc.<BR>
+1 (212)-786-6212</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">csilverstein@abeonatherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:</B><BR>
Andre&rsquo;a Lucca<BR>
Vice President, Communications &amp; Operations<BR>
Abeona Therapeutics Inc.<BR>
+1 (212)-786-6208</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">alucca@abeonatherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ =@$G P$1  (1 0,1 ?_$ ,8  0 " @(# 0$
M       '" 8)! H" P4!"P$!  (" P$!              4&! <! @,("1
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M)DH RCM5XNG'J$= 5 $NVIWTIJYQ_P ?TL199&]/5=1<EH!2)"#N9*'U$-0
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MVX=\)#OZBJ"=DAIMD<#]W;50QX*:\MVM5?-UAEYXK2]A#/AH@^\+4A)"11W
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M;!PIC6;*TY \D6,C6(,S5<B3^EXU6 T;<[N+@52%C7CPK@(J,6/L .'"JY1
M6IA#;GQ%V:.X\Y^:7R5PUB0S5Y/+S2.GB!][#R '[VM5_*G=WY!AORRR>F6O
M 56G-(^3O]"?M4^9)_=U\7VJK=[>7 #BA5,8/.7/&USE>V"C><U3[3)U34\_
M>91HD P39X#T%%X2F, )&L]Q$INTHL  9<^O7Y!MN\^\>X9+]<;?#'Q_RX%,
M3\(P?N(I]SGU'\0/ :\NQ+GM#M/ QV+9"R-_)ZYF$J\7(^T&OVH/2/TGQULE
M-[CG 8Y3$/R]X]'(<HE.0V3JL8IBF#8Q3%%^(&*8!V$!^.J/_DGO <1C;VO^
MR?\ JU<_\Y=IG@<C9T_VB_UZZO<1R/P+[6?NM.,C\=\OX[R-P:Y?'0)DV QU
M;(RSM,1R$I-F%^Z=1\8LH$8G0[/(&DX\>DW<KS]RT(83H^&^Y,'E^_\ X]%E
MFK:>#NO&UZ32(5,P"\ ">?44;6_[Q58\#K2$>9Q/8W?AO,/<0S=KY#_$6-PP
MB);C4#EL8[E_[MF4<M=U)D]9R3-I(Q[IN^8/VR#UB]:+)N6CQFZ2(NV=-7")
MCI+MW"*A3D.41*8H@("(#KY=961BC@AP:$'@01S!'F-?2:LKJ'0@H14$<B#R
M(UU=\B4&L9 _<XXY;VJ.1E&M0X_1F0(AHY(11 EGK./)\T _42.4Q%#Q;M[Y
ME+</J+I$. @8H#K?=E>3V?P1.;=MK2WAC)_LM(NX?I H?H3K1]Y:07?S9")P
M&6.T$@']I8VVG]!-1]0#KM(ZT%K>6FFFNK7Q#51Q#^XXYOXPIC1M'5+*.+W=
MIL,:@F*+8DZO7\4Y$7D&S=/H1375G["],(]/P=*;?SCOOWN0')?">*O[HEKF
MWN BGQV[I8Z5_NJOZAY:T;V^1C_F/)V-L +>> LP\-VV*2H_YS-^LZMI^XYM
M,Q7?;,ML;%.S-&]VRYB:HSO2'UG$*I,O+"=OU?$H'D:ZV,/^(%$!\!'5=^$[
M>*?OJ-Y!5HK:9U_O;0O]#'4_\QSR0]E2(AH);B)&_"I;^E1J'N/G/GG/A[!>
M(,78^]EG/"E+HF.*?6JZ[B\B55FQE(^-@F2)9Q%N%>ZB&GE ,\.)A,H=1<QC
MB8PB(R>9[/[3R>6N<A>]T6?NIIW9@8W)!+'TUW?N_;^CAJ-Q'=?=&.Q=O8VG
M;=U[:*%%4B10" H]7V_O<_Q.I@_ZH7N,_P#\6.1/_P!G5?\ X>U&_P"0>R?_
M -ILO_M/_K:D?\\=X_\ ZW>?_<7_ %=:T>=\[[A?.3*'$;)$'[5><L'9"XX9
M?A;>WR$XL,#8WS^M!/5^44KJR\>C NF<6SDHKS9A,HJ  *@%*7N'ZKSVC#V9
MVG89&QE[AM+NROK9D,85E ;:PW4)8$D&G(>'D-4ONJ7N[NB]Q]Y%@KJVO+.X
M#B3<&)7<IV\ I !%?'Q\SKMY6>0<1-9L,JU !=1D%+2#8#  E\PRCW#E$# .
MX"'<3#?7S? @DG2-OM9P#^DTU]!SN8X'D7[E0G]0KKK7_MDJA$R6 N3V>Y)%
M-_DG)G(B6A;%8'9$G$H>,A8"&LJ;/U%0AGO:=SMS>.5R=SH54$AQ 3% =;Q^
M=KF1,Q88A/38P6095' 59F6M.7!44#R&M,?"=O&^)OLJ_&]FNRK,>=%4-2O/
MBSDGZ\==FW6B=;LU7?EQC>N9=XO<@L;VR.92<';</Y!C'#=^W3<H(N1K$DO&
M21"*E,!'D1)HHNFZ@;'271(<H@8H#J:[<OI\;G[.^MF*RQW,9!'#AN%1^!%0
M1X@TU#]P6<.0P=W9W"AHI+>0<?/::'\0:$'P(KK45^VNLLW.^VRA%S#U1XWI
M>>LK5:!*H.Y640=&K6A1HCOX@AZW9GBI0_AW1 /  #6Q_G""*+O@R1"AELXG
M;ZGUI7_151^C6O\ X8FEE[,"2&HCNY57Z#TM3_28G].JR^\W0JQE+W6O:4QU
M=8U&9J-OLZ,58X=R0JC66B@R=7GCF,=I' Q%F3\&H)+$, E.D<Q1 0'4[\8W
MD^/^/>XKVU8K<Q1U5AS!Z3 $?45J/KJ$^1[2"^[\P%G<J&MY'HP\".HI(/T/
M(_37:1;MT&B"#5J@BV:MD4V[9LW3(B@W01(5-%!!%,I4TD4DR@4I2@!2E
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M.]P"J)2CLU0W"AIP!)) '/5Z[\G[=M^W)'[G5WQF]/0A(9WK5%6A7C45XD
M$GEK63@7W>,O'QC1Z5Q)]GGE?:L,4NHP%:QQ)>NA'QZU0A8]&,A#M7;RG2+:
M11!HV*'F$Y!WW1W.*AA$1&]Y?XWQOOYKKN+N7'1Y261FD&VIWL:M4!P1Q/(J
M*>6J5B?D'(&QBML!V[?R8V.-5C.Z@V**+0E#7@.>XU\]3I_U7.=<4V&0LOLL
M\KFT:@'=>NHBZP$JY;MB_6553C$:H9TX.0@#L3ZHF'PW#41_P][2D;9!W1CR
MYY HP!/X[Z?IU*GOSNB-=\W;=\$'.C@D?HV:U2->:5#RM[VV,^5.,\2Y@A['
M5.(F8E\O8&FJ:XKN9W.1L78?RW-.<;C7E0VFK-.0\9%-XQ0ICD>"9L'U1+T%
MV$W:]WC_ (LG[?O[FV:&3)0]&X5]T CEFA42[O!%)<M_#ZM4%>Y+6_\ DR'.
MV5O<+-'CYNK 4*S&2**4F/;^\S *%/CZ==SS7S%KZ0TTTTTTUK5]TW U8RMQ
MAMUZ<,TDKOAI@M<ZO,ID3*Z&.16;ELL"X5,8@J1LG%]2G0(CT.4$SE#?<#:N
M^6^W;3,]ISW[*/?V*F6-O&@IO0G^%EKP\P"-:Q^5\#:Y7M:7(, +ZR'41J<=
MM0'0_P!EAQ^A (UU+M?&NODG5J^#-</:N8''>)*1-4B>2X>:<)J_R&:UI)U8
MG0;;#N;LQ8]/^7;5P^/[4WG>N,A\/=*Q_! 7/_5U:NQK8W?>&.A !'NE8_@E
M7/[%UH,YVWMOD[FORSOK1V9^QLG(7*[F.>'#I,O&,K?)Q,8;I_U2E81Z90#^
M!0#7[U]I6AL.UL=:,*.EE%4?4H"?VDZP>Z;H7O<N0NU-5>\E(/T#D#]@U5,J
MBB)R+(] K(*)KH@H4ITQ51.55,%"F Q3$$Y W 0$!#XAJPT!X'D=0-2.(YC7
M]2/@;R[Q'S-XX8]RGBNPL7ZR=<A(:]57OMRV"@W6/BVJ$Y6K!&)F!9DHW>)G
M,V5$A47C42+)")#AM\"]W=MY'MC-S8_((0-[-&]#MD0D[64^-1S',&H/'7W'
MVKW!C^X\-#?6#@G8JNO#=&X W*P\./(\B*$<-7,U6-6/4>Y8RE2,(XTO&7,D
M3*-?HN.ZU*VNT2ZP=7E8J(:G<K@@B @=T]<B0$FZ)?KKKG(F4!,8 UFX['W6
M5OHL;8J7NYI BCS)-/T <R? <=8>0OK7&64N0O6"6L*%V/D *_I)Y >)X:ZF
MOMZ\:#^\WRTY">X3S.HWZDX^LWKW&>'<5SJTJTAGBC "!"Q!#QSJ.=*Q6-JT
MY*H[,FH0CVP2:BH[]I0H_0_>><'QCV[9]F=L2[,R0)9I5H6%?N;B"*RL*"OV
MQJ!XC6A.T<+_ ,1\_=]W=QQ;\0"8X8FJ :?:.!!I&IXT^Z1B? ZWA?\ 1/\
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MI5M-9+70HKD(PPHO..+\I? 9P5P*VE"O$$TX=PR$R&R@#W-D["O;F ;(6^$
MNO>7&/6?J[TVI(;<S[1'TZLE10U<-QX<N-?/<&<%A/F2;;VD%^T/2V/N:,7
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M^S4Q],PZ2CO,%TK\XY2>_P!P:ZPC[/,(18HEE#('*FW,@B+=04>M27@AQ/\
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M&1FE>,%F*OM4*C,0%))(%0*Z[OFKZ[7%Q6(CBFR$)E9G!<(JQ*Y"J&3<Q+J
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M^SMVECQ][;+.02K2(M)#(@;:H8_RFV$J.8W T->I[@O[?"7UW.L3WUG<M""
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M9,R>IQ7',)L8.DLS!@5;(O\ 9PY'WFQR8E0%+$7'()@ R?=6M! C2EV\Q]8
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AW([?.+MC*7&'%NVS;U=AAZ#;M^T?;TJD=2AW4IZZ:__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
